Eli Lilly Grew 47.6%. Its Margin Went the Other Way.

ELI LILLY & Co reported Q2 FY2026 revenue of $22.97 billion, up from $15.56 billion in Q2 FY2025. That is an increase of $7.41 billion, or 47.6%, year over year. With no earnings release or consensus estimates supplied, the proper comparison is the same quarter a year earlier rather than an external forecast. The latest quarter also represented a 16.0% sequential increase from Q1 FY2026 revenue of $19.80 billion. The financial figures are drawn from the supplied quarterly table and the Eli Lilly Q2 FY2026 Form 10-Q.

EPS increased to $7.94 from $6.29 a year earlier, a gain of 26.2%. That is substantial in absolute terms, but it lagged the rate of revenue growth by more than 21 percentage points. EPS also declined 3.9% sequentially from $8.26 in Q1 FY2026 even as revenue continued to rise. The divergence is the quarter’s central tension: the business became much larger, but the incremental revenue did not translate proportionately into per-share earnings.

The supplied operating-margin column represents pre-tax margin for this company. On that basis, margin declined to 40.2% from 43.6% in Q2 FY2025, a contraction of 3.4 percentage points. It also fell from 44.7% in Q1 FY2026. Even after those declines, the quarterly pre-tax margin remained above FY2025’s 39.5%, so the result is better described as moderation from unusually high recent levels than a collapse in profitability.

Table-derived free cash flow increased to $10.69 billion from $3.09 billion a year earlier and $5.33 billion in Q1 FY2026. That movement is favorable, but it should not be overinterpreted because the supplied instructions identify free cash flow as a less meaningful measure for this analysis. Gross margin was not disclosed, which prevents an assessment of whether the pre-tax decline began in product economics or arose from operating expenses and other pre-tax items.

The quarter reinforces the strongest part of the case: Eli Lilly is sustaining unusually rapid growth from an already large revenue base. FY2025 revenue was $65.18 billion, 44.7% above FY2024, and Q2 FY2026 growth remained above that full-year rate. Revenue for the first two reported quarters of FY2026 totaled $42.77 billion, although the supplied materials do not provide full-year guidance against which to judge that pace.

The weaker element is operating leverage. A company valued at 37.7x trailing earnings ordinarily needs not only high revenue growth but also durable conversion of that growth into earnings. Q2 EPS growth of 26.2% remained strong, yet it fell well short of the revenue increase, and the 3.4-point year-over-year contraction in pre-tax margin confirms that the difference was not merely a share-count effect. The absence of a supplied press release means there is no grounded management explanation for the margin movement, so attributing it to manufacturing investment, research spending, product mix or other causes would be speculation.

Capital also deserves attention. The latest supplied XBRL points show $47.86 billion of debt, $8.95 billion of cash and $33.88 billion of equity. Debt therefore exceeds reported equity, although the quarter’s earnings and cash generation provide meaningful internal capacity. The supplied data instruct against relying on net debt or ROIC, so the relevant observation is narrower: the capital structure raises the cost of an execution error, but the current level of profitability does not indicate immediate balance-sheet stress.

Overall, the print is operationally bullish but not enough to create an obvious valuation gap. Faster revenue, higher EPS and stronger table-derived cash generation improve business quality. The margin contraction limits the degree to which one quarter should lift normalized earnings expectations, particularly without guidance or management commentary.

There was no prior SageNoodle company record, so this is an initial fair-value estimate rather than a revision. The valuation uses the supplied trailing EPS of $29.80 and explicit P/E scenarios. An earnings multiple is more useful here than EV/EBITDA because EBITDA was not provided, while free-cash-flow yield and ROIC are not treated as meaningful primary measures under the supplied company classification.

The bear case applies 28x trailing EPS, producing $834.40 per share. That outcome assumes the Q2 margin contraction is an early sign that earnings growth will continue to trail revenue growth and that the market reduces the premium attached to the company. The multiple would still recognize considerable business quality, but it would not capitalize the current growth rate indefinitely.

The base case applies 38x trailing EPS, producing $1,132.40 per share. This assumes rapid revenue growth persists long enough to justify a premium valuation, while pre-tax margin remains broadly around current annual and quarterly levels rather than expanding without interruption. The selected multiple is close to the current 37.7x P/E because this quarter strengthened the growth case but did not establish better incremental profitability.

The bull case applies 48x trailing EPS, producing $1,430.40 per share. It requires the Q2 margin decline to prove temporary and earnings growth to reconnect with revenue growth. With probabilities of 25% for the bear case, 50% for the base case and 25% for the bull case, probability-weighted value is also $1,132.40 because the scenario multiples are symmetrically distributed around the base case.

Against the current price of $1,123, estimated upside is only 0.8%. Under the stated verdict rule, that makes Eli Lilly fairly valued: fair value is neither at least 15% above the market price nor at least 15% below it. The quarter supports the existing market premium, but it does not provide enough evidence to expand that premium further.

The main downside risk is that Q2’s margin contraction persists. If pre-tax margin remains below the 43.6% recorded a year earlier while revenue growth slows, EPS could decelerate faster than the base valuation assumes. A lower multiple and weaker earnings trajectory would then compound each other, which is why the bear case sits 25.7% below the current price.

A second risk is capital intensity or financing pressure. Debt of $47.86 billion exceeds equity of $33.88 billion, and the supplied data do not provide maturity schedules, interest costs or restrictions needed for a fuller assessment. Continued strong earnings could make that structure manageable, but a material operating setback would reduce flexibility.

The opposite error is also possible. The valuation could be too conservative if Q2’s lower pre-tax margin reflects temporary spending or timing and if revenue continues growing near its recent rate. In that case, current trailing EPS would understate prospective earnings power, and a 48x multiple could be supported by stronger future per-share earnings rather than multiple expansion alone.

Finally, the lack of an earnings release constrains this update. There is no supplied guidance, product-level performance, pricing-versus-volume bridge or management explanation for the quarter. The next filing could therefore materially change the interpretation of both growth quality and margin durability. Until that evidence arrives, the most defensible conclusion is that the business improved faster than EPS, while the stock already discounts much of the improvement.